Allogene Therapeutics Inc (ALLO)
2.98
+0.02
(+0.68%)
USD |
NASDAQ |
May 15, 16:00
2.98
0.00 (0.00%)
After-Hours: 16:06
Allogene Therapeutics Revenue (Quarterly): 0.022M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.022M |
December 31, 2023 | -0.044M |
September 30, 2023 | 0.043M |
June 30, 2023 | 0.044M |
March 31, 2023 | 0.03M |
December 31, 2022 | -0.04M |
September 30, 2022 | 0.049M |
Date | Value |
---|---|
June 30, 2022 | 0.086M |
March 31, 2022 | 0.061M |
December 31, 2021 | 75.65M |
September 30, 2021 | 0.049M |
June 30, 2021 | 0.044M |
March 31, 2021 | 38.34M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.044M
Minimum
Dec 2023
75.65M
Maximum
Dec 2021
8.795M
Average
0.044M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
Agenus Inc | 28.00M |
BioCryst Pharmaceuticals Inc | 92.76M |
Novavax Inc | 93.86M |
Vaxart Inc | 6.625M |
aTyr Pharma Inc | 0.235M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -65.00M |
Total Expenses (Quarterly) | 69.53M |
EPS Diluted (Quarterly) | -0.38 |
Enterprise Value | 120.87M |
Profit Margin (Quarterly) | -295.5K% |
Earnings Yield | -61.07% |
Normalized Earnings Yield | -61.07 |